Loading
companiesCompany
Ryvu Therapeutics
Ryvu Therapeutics is a Poland-based biotechnology company running 5 late-stage cancer trials of RVU120, MEN1703 and Glofitamab in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and hodgkin lymphoma.
Also called: Ryvu Therapeutics SA
Overview
Ryvu Therapeutics, based in Krakow, Poland, is a biotechnology company. A clinical-stage drug discovery and development company focused on novel small-molecule therapies addressing emerging targets in oncology. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RVU120, MEN1703, Glofitamab and Ruxolitinib in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms, hodgkin lymphoma and myeloproliferative neoplasms. The largest, NCT06397313 (RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis), plans to enrol 230 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Krakow, PL
Scorecard
All companies#329of 1244 companies, score 12
- phase 1/2 +2
- targets +2
- modalities +2
- registry trials +6
0 approved, 0 in phase 3, 2 earlier, 1 targets, 8 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 2small molecule (kinase inhibitor)
MEN1703 is an experimental small molecule (kinase inhibitor) from Ryvu Therapeutics in phase 2 trials for hodgkin lymphoma, aimed at FLT3.
Phase 2Small-molecule inhibitor
RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia.
Similar pages
- TargetSLX4
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
- JournalCurrent hematologic malignancy reports
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Hodgkin lymphoma, Acute myeloid leukaemia.
- TargetDDX41
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
- JournalLeukemia & lymphoma
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Hodgkin lymphoma, Acute myeloid leukaemia.
- TrialA First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Myelodysplastic syndromes / neoplasms (MDS), Hodgkin lymphoma, Acute myeloid leukaemia.
- JournalLeukemia research
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
- TargetFANCC
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
- TargetGATA2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.